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Background: Clinical psychiatry has always been limited by the lack of objective tests to substantiate diagnoses
and a lack of specific treatments that target underlying pathophysiology. One area in which these twin failures has
been most frustrating is major depression. Due to very considerable progress in the basic and clinical neurosciences
of sleep-wake cycles and underlying circadian systems this situation is now rapidly changing.
Discussion: The development of specific behavioral or pharmacological strategies that target these basic regulatory
systems is driving renewed clinical interest. Here, we explore the extent to which objective tests of sleep-wake
cycles and circadian function - namely, those that measure timing or synchrony of circadian-dependent physiology
as well as daytime activity and nighttime sleep patterns - can be used to identify a sub-class of patients with major
depression who have disturbed circadian profiles.
Summary: Once this unique pathophysiology is characterized, a highly personalized treatment plan can be
proposed and monitored. New treatments will now be designed and old treatments re-evaluated on the basis of
their effects on objective measures of sleep-wake cycles, circadian rhythms and related metabolic systems.
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Nowhere is the loss of confidence in the diagnostic pro-
cesses in psychiatry more acute than it is in relation to
the major depressive disorders [1,2]. This is reflected
not only in the acrimonious debate about proposed
changes to the Diagnostic and Statistical Manual of
Mental Disorders (DSM)-5 [3], but also in the degree of
professional discord [4] and the sustained social critique
of the current concepts [5,6]. More profoundly from a
therapeutic perspective, it has contributed to the with-
drawal of major pharmaceutical industry support for new
drug development [7].
This all occurs at a time when internationally there is
widespread recognition of the premature death and dis-
ability attributable to mood disorders, reflecting their
early age-of-onset, high population prevalence, chron-
icity, comorbidity with physical illness and the degree of* Correspondence: ian.hickie@sydney.edu.au
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reproduction in any medium, provided the orresultant impairment [8-10]. To reduce that burden,
earlier identification and enhanced long-term care of
those who are at risk or are in the early phases of life
threatening or chronic disorders has been prioritized
[8,11-15].
However, this key ‘pre-emptive’ approach is compromised
by poorly-validated and entirely descriptive diagnostic
systems [11-15]. Further, these systems were based on
the experiences of middle or older age cohorts with
recurrent or persistent disorders. By contrast, one of the
few concepts that can be supported neurobiologically is
that early-onset major depression (that is, develops before
age 25 years) is pathophysiologically distinct from late-
onset major depression (that is, develops after the age of
50 years, and typically in association with other genetic or
vascular risk factors [16-19]).
When the current criteria are used as the basis for
identifying biomarkers of a risk or illness course in very
mixed clinical populations of those experiencing major
depression, they result in very poor specificity. Previous
attempts to link major depression to dysregulation oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for this reason [20,21]. In parallel, there has been a fail-
ure to link major depression to any clear set of genetic
risk factors [22]. Most importantly clinically, the out-
come of current treatment trials is highly compromised.
The examination of very heterogeneous groups of sub-
jects, and particularly the inclusion of those with lower
levels of severity of illness, appears to contribute sub-
stantially to the general failure to identify specific bio-
markers and the large differences between active and
placebo therapies [23-25]. Depression treatment is also
sub-optimal due to the general lack of rapid onset of ac-
tion. The risk of suicide or other self-harm remains high
during the period of acute depression and only decreases
substantially in parallel with the provision of effective
treatments [26].
While various phenotypically-defined subgroups (for
example, severe, melancholia, anxious or psychotic de-
pression) have been proposed historically, each subtype
has achieved only limited success against the key validat-
ing principles of specific genetic or environmental risk
factors, discrete pathophysiological pathways or unique
patterns of response to treatment. Instead, much clinical
and epidemiological innovation has switched to identify-
ing clearer points of illness onset and subsequent devel-
opmental paths, particularly those that occur from early
adolescence through to early adulthood. While this ap-
proach was first utilized for psychotic disorders [27-29],
current efforts now also focus on applying these tech-
niques to the major mood disorders [30-33].
Marked interdisciplinary progress in the clinical and
basic neurosciences of sleep-wake cycles and underpin-
ning circadian systems has opened the door to a new
way of conceptualizing at least a significant subpopula-
tion of those who present with major mood disorders.
The role that disruption of sleep-wake and circadian sys-
tems play in the risk of onset, early course, comorbidity,
recurrence, persistence and the physical health compli-
cations of major mood disorders is being rapidly elabo-
rated [34-38]. For example, our group has reported that
short or excessively long sleep duration is associated
with the onset and persistence of psychological distress
in a sample of 20,822 people aged 17 to 24 years [39].
Key findings also come from experimental studies in
healthy adults showing that delaying sleep onset or
disturbing circadian synchrony causes profound changes
in mood, cognitive function, motor activity and subject-
ive symptoms of energy and well-being [40,41]. A grow-
ing body of studies conducted in subjects with other
psychiatric illnesses (for example, psychotic disorders)
also highlights associations between sleep-wake and
circadian disruptions, concurrent mood disturbances
and metabolic and other physical health complications
[42-45].This paper provides an overview of the extent to which
current self-report and objective measures of sleep-wake
cycles and circadian systems can be used to characterize
individuals presenting with major mood disorders. It also
considers how such clinical information can be used to in-
form choice of specific behavioral or pharmacological re-
gimes and to monitor short and longer-term responses
to treatment.
Discussion
Basic science developments in relation to the circadian
clock
Circadian systems need to be considered in relation to
three differing levels of organization of information and
operation (see Figure 1). First is the way in which the
physical environment communicates (or ‘Inputs’) key in-
formation, particularly related to differentiation of night
from day, to the internal ‘master’ clock (located in the
brain’s suprachiasmatic nucleus (SCN)). Second are the
‘Intrinsic’ brain factors, consisting of the master clock
and its linked regulatory systems (notably secretion of
melatonin from the pineal gland). These contribute to
sleep onset, sleep architecture, sleep-wake cycles and
other central nervous system (CNS)-dependent behav-
ioral changes. Third is the way in which the circadian
system coordinates all other hormonal, metabolic, im-
mune, thermoregulatory, autonomic nervous and other
physiological processes to optimize the relationships be-
tween behavior and body functions (that is, the ‘Outputs’).
At the cellular level, almost all individual cells and,
hence, organ systems have their own intrinsic clocks. As
these cellular (for example, fibroblasts, fat cells, muscles)
and organ-based (for example, liver, pancreas, gut) clocks
run to intrinsically different period lengths, the differing
physiological systems need to be aligned in coherent pat-
terns. Fundamentally, the master circadian clock permits
the organism to align key behavioral and intrinsic physio-
logical rhythms optimally to the external 24-hour light–
dark cycle [46].
Molecular regulators of the brain clock
The brain’s master clock (in the SCN) is a small cluster
of pacemaker neurons in the anterior hypothalamus. It
operates a complex auto-regulatory network, utilizing a
set of transcriptional activators and repressors [47-49].
These processes are under the control of a core set of
regulatory genes including: Period – Per1, Per2 and Per3;
Cryptochrome – Cry1 and Cry2; Nuclear receptor subfam-
ily 1 – Nr1d1 (REV-ERB-α) and Nr1f2 (ROR-β); Circadian
Locomotor Output Cycles Kaput – CLOCK; and Aryl
hydrocarbon receptor nuclear translocator-like – Bmal1
and Bmal2. The transcription of PER and CRY genes is ac-
tivated by the binding of BMAL1-CLOCK or BMAL1-
NPAS2. The expression of PER and CRY genes is rhythmic
Figure 1 The master circadian clock in the human brain.
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the PER1 and PER2 expression genes. The progressive ac-
cumulation of the proteins that result from this activated
transcription, over the daily period, eventually feeds back
(via the formation of Per-Cry complexes) to reduce their
own transcription (the so-called ‘hour-glass’ effect). The
strong correlation between gene expression and circadian
transcription factor binding leads to genome-wide circa-
dian rhythms [50]. Across the past decades, it has beenwell established that the disruption of various components
of the molecular clock leads to significant changes in cir-
cadian phenotype [51,52].
This 24-hour self-regulatory process is also influenced
by a much wider set of small molecule modifiers, other
genetic factors and transcriptional repressors (for ex-
ample, deleted in esophageal cancer 1 - Dec1 and Dec2)
[53]. There are key proteins that impact on timing of the
clock (through phosphorylation) including casein kinase
Hickie et al. BMC Medicine 2013, 11:79 Page 4 of 27
http://www.biomedcentral.com/1741-7015/11/79(CK) 1 delta and epsilon (Csnk1d and Csnk1e). Selective
inhibition studies indicate that Csnk1d appears to be a
predominant mediator of circadian timing [54-56]. A
variety of other protein kinases and phosphatases can
also impact on circadian timing. The expansion of ani-
mal models (particularly in mice and zebrafish [57,58]),
utilizing genetic manipulation or new environmental or
developmental models, has created important new tools
for further unraveling the complexity of these processes.
Glycogen synthase kinase 3 beta (GSK-3β) as a therapeutic
target
Glycogen synthase kinase 3 beta (GSK-3β) plays a key
regulatory role in circadian rhythms as it phosphorylates
the mammalian Per2 protein, facilitating nuclear entry -
a key step in the auto-feedback loop. It is now more
than 60 years since the anti-manic effect of lithium was
first reported [59]. A key clinical observation relates to
its calming effect without causing overt sedation. An-
other key aspect is that its main therapeutic value is in
the longer-term reduction in symptoms of mania and
prevention of relapse. Recently, the inhibitory effects of
lithium on GSK-3β have been described [60]. However,
there is ongoing debate as to whether the characteristic
period-lengthening effects of lithium may actually be
mediated by mechanisms other than inhibition of GSK-
3β [58]. Genetic variations in GSK-3β have also been
linked with the risk to depressive disorders, and most
notably to bipolar disorder [61]. Hence, GSK-3β is one
of a number of key targets being explored with regards
to possible new agents for circadian-related sleep-wake
or mood disorders [62-64].
Circadian function and human health
The adverse health effects of a disturbed circadian sys-
tem are now under very active investigation. The major
driver behind this increased focus on the 24-hour sleep-
wake cycle and related circadian rhythms in clinical
medicine has been the rapid progress in our understand-
ing of the downstream effects on neurohormonal, meta-
bolic, autonomic nervous and immune functions (see
Figure 1). In humans, the aggregate outputs of the circa-
dian system depend principally on the ways in which the
brain, operating under genetic, behavioral (for example,
eating behavior, physical activity), as well as other exter-
nal (for example, light exposure, seasonality) and in-
ternal (for example, other sleep onset vs. awakening
systems) cues, controls the central timing of circadian
rhythms [47,65-67].
The rhythmic expression of the core clock genes operates
on a period slightly longer than 24-hours, unless it is modi-
fied or ‘entrained’ by key environmental inputs (in humans
it is most notably the daily light–dark cycle). Importantly,
the rhythmic and circadian output of the whole processhas been remarkably preserved across species, indicat-
ing its fundamental importance to survival. As ani-
mals age it would appear that the combination of
strong circadian rhythms and caloric restriction im-
parts additional advantages.Inputs to the brain clock
The input of light signals from the eye to the SCN is
critical to setting the circadian period to a 24-hour cycle.
Changing light signals indicate not only the transitions
from day to night to day but also the change in day
length that occurs across seasons. Light signals are con-
veyed by a monosynaptic pathway (that is, the retino-
hypothalamic tract) from the retinal ganglion cells (which
contain the photopigment melanopsin) to the cells of the
SCN (via a glutamatergic signal). Additionally, the SCN
receives an important serotoninergic input from the
median raphe nucleus (that is, via non-photic stimuli).
Hence, those behaviors or disorders that are associated
with changes in serotoninergic mechanisms (as well as
compounds that alter serotonin concentrations) may also
have important impacts on circadian-dependent phe-
nomena. The serotoninergic, non-photic inputs and the
glutamatergic, photic-dependent signals have opposite ef-
fects at the level of the SCN.
With regards to external cues, it is clear that in humans
the daily timing of a range of behaviors have an important
influence on circadian rhythms [67]. These include:
(i) awakening and rising from bed; (ii) light exposure, par-
ticularly to light that is in the ‘blue’ spectra (which is
most efficient in suppressing melatonin secretion) [68,69]);
(iii) physical activity and exercise, with additional effects of
duration and intensity; (iv) eating patterns; (v) social and
occupational activities; and, (vi) nighttime activity and re-
lated time of sleep onset.‘Morningness’ vs. ‘eveningness’
In humans, there is considerable inter-individual vari-
ability in the circadian phase, as well as variation in the
peak periods of key behavioral (for example, mood, con-
centration, energy), neurohormonal (for example, corti-
sol peak, regulation of thyroid hormone) and body
temperature elements. This intrinsic variability, which
appears to be largely under genetic control, can be mea-
sured by self-report along a dimension of ‘morningness’
vs. ‘eveningness’ in the preferred timing for regular sleep
schedules and other daily activities. Importantly, the
tendency towards ‘eveningness’ has been associated
with higher depressive symptoms [70,71]. In twin
studies of bipolar disorder, affected individuals (compared
with their co-twin) show greater seasonal changes in
sleep patterns and mood, consistent with the extent
to which environmental influences on the circadian
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etic sensitivity [72].
The outputs of the brain clock
The outputs of the SCN exert their influence on other
key regulatory systems; first, in the brain (see the critical
SCN-pineal/melatonin loop, Figure 1) and, second, on
other major physiological systems (via their impacts on
the pituitary and linked neurohormonal systems, thermo-
regulation, the autonomic nervous system and other sig-
naling mechanisms). The key physiological result of these
inter-linked processes is coordination of the internal en-
vironment so that the various hormonal, immune and
metabolic factors are in synchrony with each other and,
critically, with the behavior of the individual (for example,
eating, sleeping, exercising).
Lesion-based experiments have indicated that what is
lost through destruction of the SCN is not the circadian
system itself but this central coordinating role. Genetic
alterations of clock genes in mice indicate the extent to
which the coordination of key behavioral factors is dis-
turbed. For example, mice with a point mutation in the
CLOCK gene display: (i) hyperactivity over the light/dark
cycle;, (ii) reduced depression-like behavior in rodent
testing paradigms;, and, (iii) an increase in reward value
in response to self-stimulation tests [73-75]. Alterations
of clock genes also increase dopamine release, enhance
sensitivity to dopamine receptor agonists, and alter the
relative distribution of D1 and D2 receptors [76]. More-
over, Per1-2 homolog dysfunctions in mice cause an in-
crease in anxiety-like behavior and, conversely, a mouse
model of depression leads to a reduction in Per1-2 ex-
pression [77]. Accordingly, in humans, a growing body
of evidence is linking various components of the mo-
lecular circadian clock to various health conditions, in-
cluding mental disorders (for reviews, see [78,79]).
Melatonin and communication via the pineal gland
From a circadian perspective, one of the principal out-
puts of the SCN is communication with the pineal gland,
which controls the daily pattern of melatonin release
[80] (Figure 1). Again, this is a 24-hour feedback system,
whereby light exposure (through the eye and signaled
via the SCN) strongly inhibits melatonin release during
daylight hours. This is followed by a rapid rise in mela-
tonin secretion about two to three hours before habitual
sleep onset (typically mid-evening). Melatonin has a
wide range of CNS (including the SCN) and peripheral
targets. Specifically, melatonin induces sleep onset, pro-
motes optimal sleep architecture and coordinates other
physiological and behavioral aspects of the sleep period.
In turn, melatonin feeds back directly onto the SCN to
inhibit the circadian signal for increasing wakefulness. It
also competes with the activating effects of serotoninergicinputs to the SCN. In this way, endogenous melatonin (or
the appropriate use of exogenous melatonin at the right
point in the daily cycle) plays a key role in stabilization of
daily rhythms. Some of these chronobiotic effects seem to
be modulated by the interactions between melatonin and
clock genes [81].
The other key outputs of the SCN (acting initially via
the paraventricular nucleus; PVN) include regulation of
the pituitary release of key stimulating hormones and
autonomic neurons (see Figure 1). These have their im-
pacts on a wide range of peripheral organs. Most not-
ably, from a circadian perspective, adrenocorticotropic
hormone (ACTH) regulation of cortisol release from the
adrenal glands is central to the coordination of brain-
dependent mechanisms and peripheral physiology. In re-
cent years, there has also been much greater focus on
the extent to which other key metabolic functions in the
liver and pancreas have their own intrinsic circadian pat-
terns [82-86]. Importantly, food intake entrains the
liver’s clock. Ideally, these metabolic patterns should be
coordinated with signals from the SCN so that key as-
pects of feeding behavior, glucose control and fat regula-
tion are optimally coordinated [87]. Recent animal studies
indicate that synthetic REV-ERB-a/b agonists alter the
circadian timing of clock genes’ expression in the
hypothalamus and locomotor activity, while enhancing
energy expenditure and reducing fat, triglycerides and
cholesterol levels [88].
Homeostatic sleep processes
Importantly, circadian processes are one of two major
regulatory systems influencing the daily sleep-wake cycle
[89]. The other is a homeostatic process directly related
to wake duration; the longer the period awake, the
greater the accumulated ‘pressure’ to sleep again (that is,
sleep debt). While accumulated sleep pressure, in com-
bination with nighttime melatonin release drives sleep
onset, the circadian system is seen to drive the strength
and rhythmicity of daytime wakefulness. The homeo-
static sleep pressure component drives slow wave (or
deep) sleep (SWS) while rapid eye movement (REM)
sleep is strongly influenced by the circadian component
(interestingly, it was once assumed that all effective anti-
depressants shared a capacity to suppress REM sleep).
However, the optimal coordination of both of these mech-
anisms results in the maximal consolidation of sleep at
night and wakefulness during the day.
The hypocretin/orexin systems
Another important aspect is the potential role of
hypocretin/orexin, a key neuropeptide that also plays a
central role in coordination of sleep-wake activity [90].
The timing of normal hypocretin/orexin production is
critical as it contributes to staying awake (in humans
Hickie et al. BMC Medicine 2013, 11:79 Page 6 of 27
http://www.biomedcentral.com/1741-7015/11/79typically later in the day) as sleep debt increases. In both
humans and animals, absolute orexin deficiency is linked
to the narcolepsy-cataplexy syndrome [91,92], while in
animals a lack of orexin signaling increases risk of
obesity [93]. Novel orexin antagonists have been devel-
oped for the treatment of primary or chronic insomnia
and are undergoing extensive clinical trialing [94-96].
Consequently, further manipulation of hypocretin/orexin
signaling is now under consideration as another pathway
by which sleep, circadian and disturbed metabolic func-
tions may all be enhanced [87,97].
In summary, we now have much more detailed know-
ledge of the ways in which the brain responds to a range
of key environmental cues as well as the processes by
which it, in turn, regulates the many other aspects of in-
ternal physiology that demonstrate specific rhythmic
patterns (for example, hormonal, immunological and
metabolic systems) [88,98-105].
Clinical science developments in relation to the circadian
clock
In the past, the traditional organ or clinical specialist-
based approaches to clinical medicine have failed to take
into account the health effects of important daily and
seasonal fluctuations in key regulatory systems, such as
the 24-hour sleep and circadian cycles. However, along-
side the detailing of the molecular mechanisms of the
clock and its signaling systems, the clinical applications
of this new knowledge are beginning to be recognized.
Twenty-four-hour sleep-wake and circadian cycles are
now of great interest not only in sleep medicine and
clinical psychiatry but also in aging and dementia, devel-
opmental and neurological disorders, obesity, diabetes
and related metabolic disorders, immunology and infec-
tious diseases, and cancer care. While in psychiatry gen-
erally, there has not yet been an effective translation of
knowledge into clinical practice, this process has begun
recently in the field of depressive disorders.
The epidemiology and sub-classification of major
depression
Historically, various sub-classifications for major depres-
sion have been proposed. Typically, each has prioritized
different phenotypic characteristics (for example, sever-
ity, psychotic features, psychomotor change, presence of
manic or hypomanic episodes, somatic or ‘atypical’ fea-
tures) [16]. Although the more severe forms (for ex-
ample, depression, bipolar disorder, melancholia, atypical
and psychotic depression) implied a preferential response
to biomedical therapies, only the psychotic forms demon-
strate robust differences between active physical and pla-
cebo treatments [16]. To date, none of the phenotypically-
derived sub-types have been clearly linked to a discrete
pathophysiology. Further, no clear pattern of specificillness markers has been identified to aid diagnostic speci-
ficity or act as a useful proxy for personalized treatment
selection or responsiveness.
While the 1990s saw the start of two decades of inten-
sive genomic and brain imaging studies, the 1980s
had seen the groundwork laid for three decades of
population-based epidemiology and the much broader re-
cruitment of subjects with less severe, persistent or recur-
rent disorders to clinical trials. Using standardized criteria,
these studies identified large numbers of people in the
broader community who met criteria for major depressive
episodes [106]. In these broader populations, the large dif-
ferences between active and placebo treatments evapo-
rated and the differences between various physical and
psychological approaches were minimized (see [1,2]).
The unintended consequences of these movements
have been profound. On the one hand, it has led to a
sustained critique by mental health specialists who dis-
count the application of the clinical diagnosis of major
depression in the wider population and, hence, call for a
return to the earlier diagnostic systems that were derived
from more severely or persistently-ill populations. Con-
versely, those more accustomed to primary care or
population-based health perspectives sought to work with
the new epidemiology, and, particularly, those key longitu-
dinal studies from childhood or adolescence through to
adulthood. These have also been enhanced by genetically-
informative family and twin studies [107-109] as well as
relevant risk factor studies [39]. This developmental per-
spective has generated new hypotheses about lifetime
pathways (and underlying pathophysiologies) to adult de-
pressive disorders [110,111].
Early-onset depressive disorders
The one key differentiation supported by genetic and en-
vironmental risk factor research, longitudinal and treat-
ment studies and extensive concurrent neuroimaging
and neuropsychological studies is the demarcation be-
tween early (that is, less than 25 years of age) and late-
onset (typically after 50 or 60 years of age) depressive
disorders [18,111,112]. Late-onset depression has its
own clear set of vascular and other neurodegenerative
risk factors [18,113-116] and represents one of the few
psychiatric disorders where there is now a clear patho-
physiological model (that is now being used to underpin
population-based prevention and early intervention as
well as clinical practice) [19,117-120].
It is for those with early-onset depression, however,
that new insights are desperately required. A new wave
of clinical studies is focused on younger people and
within those cohorts at least three clear trajectories of
illness are increasingly apparent (see Figure 2). The most
common would appear to be that dominated by child
and adolescent anxiety, with the onset of more discrete
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Figure 2 Pathophysiological pathways to early-onset depressive disorders. There are at least three common trajectories that lead to
depression in the teenage and early-adult years. These are characterized by (1) ‘anxiety-central nervous system reactivity’, (2) ‘circadian and 24-
hour sleep-wake cycle dysfunction’, and (3) ‘developmental brain abnormalities’. The six corresponding phenotypic patterns have distinct ages of
onset and characteristics. From age 8 to 10 years onwards these processes are transformed by key neurobiological phenomena: (a) puberty,
(b) adolescent brain development, and (c) sleep-wake cycle [see 122].
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this common form which offers perhaps the greatest
hope for broadly-applied prevention and early interven-
tions utilizing well-founded cognitive and behavioral
strategies [121]. The second, and largely ignored by the
traditional mood disorders literature, is that related to
other childhood onset and adolescent-related conduct,
behavioral and attention disorders. The third appears to
be a pattern of mood disorders which may well be char-
acterized better as disorders of energy or activity due to
underlying perturbations of sleep-wake cycles and linked
circadian rhythms. This last type is the subject of the re-
mainder of this paper.
Mood disorders and sleep-wake and circadian cycles
As the debate about the pathophysiology of mood disor-
ders has focused primarily on the assumption that the
core pathology(ies) must relate to disordered emotion,
other features such as sleep-wake cycle and circadian
changes have been downplayed. Most typically, major
depressive disorders (see Table 1) have been associated
with a wide range of perturbations of sleep and circadian
physiology. Up to 60% of young persons with depressive
disorders run an illness course characterized by marked
delays in the sleep-wake schedule [123], and these fluc-
tuations are often accompanied by changes in subjective
energy, cognitive functions and mood. Very recent epi-
demiological evidence emphasizes that this pattern is
clear from the onset in early to mid-adolescence and,
contrary to previous dogma, does not develop solely in
the early or mid-adult period [124]. Other evidencesuggests the extent to which this pattern of low energy,
as distinct from depressed mood, has its own set of gen-
etic and environmental determinants in adolescence
[109], as well as in mid- or later-life [125-130].
Key features, such as onset of illness episodes, in rela-
tion to changes in sleep patterns and/or season have
not necessarily been emphasized. For some patient sub-
groups these involve characteristic shifts into or out of pe-
riods of prolonged depression, oversleeping, low energy
and apathy. For others (notably those on the bipolar
spectrum), this may also result in discrete periods of de-
creased sleep, high energy, increased activity and irritabil-
ity or excitement. Other indicators of disturbed circadian
rhythm are observable in patients with major depression
including changes in the normal patterns of diurnal mood
variation or loss of normal daily variations in body
temperature (with elevated mean nocturnal temperatures
resulting in the perception of nighttime ‘sweats’). The pos-
sible role of the circadian clock in the pathophysiology of
depression is also supported by post-mortem histological
anomalies in the SCN of depressed individuals [221].
Typical and atypical forms of depression
A large number of sleep or circadian abnormalities have
been documented across the various forms of major
mood disorders (see Table 1). In some forms of depres-
sion, notably those ‘typical’ or ‘melancholic’ forms asso-
ciated with early morning wakening and marked diurnal
mood variation (often occurring in older rather than
younger subjects), there may also be a marked change in
the normal circadian variation in motor activity, with a
Table 1 Characteristic sleep-wake and circadian features of selected mood disorders
Mood syndromes Sleep-wake and circadian features
Major depression ● Subjective sleep-wake complaints (often preceding the onset or recurrence of depressive episodes)
Difficulty falling asleep, staying asleep or early morning awakening [131,132]
Disturbing dreams [133]
Unrefreshing shallow sleep [132,134]
Daytime fatigue and sleepiness [132,134,135]
● Macro and microarchitecture of sleep
Abnormal sleep duration [136]
Prolonged sleep onset latency [136]
Shortened REM latency and increased rapid eye movements [136-140]
Increased sleep fragmentation [136,138]
Decreased SWS and increased REM sleep and (especially in the first sleep cycle) [136,140]
Reduced slow wave activity and number of slow waves [136]
High comorbidity with sleep-related breathing disorders [141,142]
● Biological rhythms
Abnormal sleep phase [71, 143 ]
Reduced melatonin secretion [144-149]
Increased 24-hour levels and variability of cortisol secretion [145,150,151]
Reduced circadian amplitude and increased nighttime body temperature [147,151,152]
Reduced heart rate circadian amplitude [153-155]
Depressive symptoms associated with increased nocturnal blood pressure in males
Abnormal cytokines, neurotransmitters, endocrine (for example, melatonin, cortisol, thyrotropin) and neuroimmune circadian
rhythms [97,144-148,151,156-168]
Abnormal circadian mood variations [157,159,169-171]
Possible seasonal variations (not exclusive to seasonal affective disorder) [172]
● Increased depressive symptoms are associated with more pronounced misalignment between melatonin, temperature and
sleep-wake rhythms [173]
Depression in youth ● Subjective sleep-wake complaints
Difficulty falling asleep and staying asleep [174]
Difficulty waking up in the morning [175]
● Macro and microarchitecture of sleep
Lower intra- and inter-hemispheric coherence in delta and beta activity, especially in girls [176,177]
Otherwise similar features to those seen in adult depression, but expressed to a lesser degree [177-184]
● Biological rhythms
Higher levels of ‘eveningness’ preference [70]
Lower circadian amplitude [185]
Delayed sleep phase and melatonin onset, especially in those with bipolar disorder [123,212]
Elevated evening/nighttime cortisol levels [186,187]
Late-life depression ● Macro and microarchitecture of sleep
Lower increase in REM sleep duration [136]
Otherwise similar features to that seen in adult depression, but more pronounced [136]
● Biological rhythms
Increased early morning awakenings [188]
Abnormal melatonin levels [189]
High prevalence of abnormal blood pressure circadian rhythms [190]
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Table 1 Characteristic sleep-wake and circadian features of selected mood disorders (Continued)
● Sleep and circadian disturbances have been associated with cognitive decline, relapses and mood deterioration [43,116]
Bipolar disorders ● Characterized by episodic periods of sleep loss (that is, switching from wake to normal duration sleep state and back again
over a 24-hour period) [191,192]
● High prevalence of hypersomnia, especially ‘morning hypersomnia’ [193-195]
● Insomnia often occurring before and during manic episodes [196]
● Insomnia or hypersomnia often occurring before and during depressive episodes [196]
● Macro and microarchitecture of sleep
Depressive phase: longer sleep onset latency and greater REM fragmentation, but otherwise similar to people with unipolar
depression [197-200]
Manic phase: Prolonged sleep onset latency, decreased sleep duration, lower sleep efficiency, shortened REM sleep latency
and increased REM activity and density [201,202]
● Disturbed biological rhythms
Short circadian period [203]
Possible hypersensitivity to light suppression of melatonin [204,205]
Diurnal variations in the direction of mood cycle switch [206]
Possibly enhanced disturbances in thyrotropin rhythms [207]
Onset of mania episodes at key points in seasonal transitions [72,208]
High prevalence of evening chronotypes (that is, preference for late bed and wake times) and late sleep onset, especially in
younger individuals [209,210]





Hypersomnia (typically in winter-onset) [212-214]
Insomnia (typically in summer-onset) [212,214]
● Disrupted biological rhythms
Delayed melatonin, cortisol and temperature rhythms [215-217]
Seasonal pattern of changes in symptoms [218]
Increased sensitivity of melatonin to light in the winter and decreased sensitivity in the summer [219]
Dysthymia ● Similar features to that seen in major depression expressed to a lesser degree [220]
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phase advanced pattern. That is, the end result is being
awake and potentially more agitated in the early hours
of the morning. Overall, however, such forms of depres-
sion are associated with psychomotor slowing and a re-
duction in total daytime activity [222-226]. These severe
forms of depression are also typically associated with de-
creased appetite and weight loss.
By contrast, ‘atypical’ forms of depression, which are often
seen in teenage and young adult patients, are associated
with later sleep onset, later sleep offset, prolonged rather
than shortened sleep, daytime tiredness and fatigue as well
as loss of motor activity in the mornings. These disorders
are often associated with overeating, weight gain and in-
creased risk of metabolic dysfunction. These patterns sug-
gest underlying phase delay in the circadian system.
Loss of circadian hormonal patterns in depressive disorders
The symptoms of circadian disturbance seen in sub-
groups of depressive disorders are also accompanied byobservable changes in the normal circadian patterns of re-
lease of ACTH (regulating cortisol release) and thyroid-
stimulating hormone (TSH; regulating thyroid hormone
release). The typical morning peak of cortisol release is
normally well matched to the associated feelings of energy
and our capacity to cope with physical stressors. The
resulting altered patterns of cortisol release are generally
consistent with underlying phase advance or loss of syn-
chrony with other elements of the daily cycle. Changes in
such key patterns of cortisol release appear to correlate
also with daytime feelings of lack of energy and fatigue.
Similarly, while there is evidence of changes in the ampli-
tude and timing of the TSH release pattern, it would also
generally suggest a pattern of phase advance.
Common genetic factors in circadian systems and risk of
mood disorders
Of additional importance to the increased interest in
sleep-wake cycles and circadian rhythms and risk of mood
disorders, has been the recognition of the commonality
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those genes which may increase risk of mood disorders,
particularly bipolar disorder [227]. While further studies
are required, so far, variations of Per3 have been associated
with age of onset of mood disorders, response to treat-
ment and circadian mood variations [228] and Per 3,
Bmal1, CLOCK, Nr1d1 and Nr1f2 have all been linked to
bipolar disorder [229-234]. Another related set of studies
has begun to investigate whether the same genetic factors
that predict response to antidepressant medicines also
predict response to specific circadian-based therapies,
such as light therapy or sleep deprivation [235].
Disturbances in melatonin secretion in mood disorders
In those with major depressive disorders, disturbances in
the amplitude and rhythm of melatonin secretion have
been described [see Table 1]. These are similar to those
described in a range of other sleep or neuropsychiatric
disorders associated with disturbed circadian function.
Although phase advance and phase delay in melatonin
secretion have both been reported, phase advance
(largely in middle age and older cohorts) may be more
typical. Additionally, changes in the rate of rise of even-
ing melatonin and the amplitude of the melatonin re-
sponse have been associated with various mood disorders.
The findings with regards to phase advance versus phase
delay for melatonin, cortisol and other circadian parame-
ters in patients with major depression may be strongly
influenced by the age of the subjects. Various rela-
tionships have been reported between the severity of
these changes in timing or amplitude and reported sever-
ity of depression or degree of sleep disturbance. For those
with bipolar disorder, there have been distinctly different
patterns of melatonin secretion reported during the manic
(phase advanced) as compared with the depressive phase
(phase delayed).
For those with major depressive disorders, the role of
sleep-wake cycles or circadian perturbations may be quite
different at various life stages. For the early-onset group, it
is likely that sleep-wake and circadian disturbances repre-
sent one discrete pathway to disorder; while for those with
the late-onset sub-type, sleep-wake disturbance may be
linked with concomitant structural and functional brain
changes due to underlying vascular or neurodegenerative
processes (see review by [19,236-238]).
The challenge of bipolar depression
One of the areas of greatest therapeutic frustration has
been the treatment of the depressive phase of bipolar
disorder. Importantly, conventional monoamine-based
medications are of least benefit in these patients. At this
time a new range of second generation antipsychotic
medications, anticonvulsants and other mood-stabilizing
agents form the basis of care (often in combination withantidepressant agents). Conventional lithium therapy is
not an effective monotherapy for bipolar depression.
Given the very strong circadian features of bipolar dis-
order, and this failure to develop effective therapies for
the depressive phase based on monoamine targets, it (along
with the other circadian-like mood disorders such as
seasonal affective disorder, winter depression, seasonally-
sensitive unipolar depression, bipolar spectrum disorders,
atypical depression) may benefit from a new circadian-
based approach to treatment selection. A recent report
suggests that adjunctive use of a novel melatonin
agonist (ramelteon) may help to prevent relapse of
bipolar disorder, and most notably relapse into the
depressive phase [239].
The importance of internal desynchrony
Various authors (see [34,35] for review) have proposed
that what may be most characteristic of the neuropsychi-
atric disorders is the extent to which they result in
‘desynchrony’, that is, both loss of synchrony between
the key behavioral and physiological events as well (see
Figure 3) as loss of synchrony between the various
physiological events (that is, in the CNS itself and the key
peripheral systems). Many human studies of dysregulation
of central hormones (for example, HPA axis), or im-
mune function, in those with major depression and a
range of other neuropsychiatric disorders have moved
their emphasis away from recording absolute changes
in serum levels to evaluating putative changes in re-
lation to deviations from normal circadian patterns
[146,151,165,167,168,240].
Major depression appears to be characterized by loss of
synchrony between the different sleep-wake, mood, cogni-
tive, motor, hormonal, immune, thermoregulatory and/or
metabolic aspects of the normal circadian rhythm [35]. In
addition to its detrimental effects on the sleep-wake cycle,
this internal desynchrony may well account for the range
of somatic symptoms (fatigue, temperature dysregulation,
muscle pain) and other physiological abnormalities that
have been linked to various forms of major depression.
While it has previously been assumed that circadian sig-
naling mechanisms from the brain to the periphery (see
Figure 1) are maintained largely by hormonal signals, re-
cent evidence suggests a key role of daily variations in
body temperature [241].
It is tempting to postulate that the blunted amplitude of
the temperature rhythm commonly found in patients with
major depression could be a major driver of internal
desynchronization, and, hence, of many of the somatic
symptoms of depression as well as some of its metabolic
and immunological complications. If this were so, restor-
ation of the normal variation in body temperature across
the 24-hour cycle would be a key therapeutic target. This
may be manipulated by strategies designed to increase
Figure 3 The normal synchronous relationships between sleep and daytime activity and cortisol, melatonin and body temperature.
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morning – for example, with vigorous exercise) or de-
crease body temperature in the evening (that is, through
environmental or pharmacological manipulations).
Clinical studies of young people with major depressive
disorders
Monitoring the 24-hour sleep-wake and activity cycle
A key aspect of those studies that focus on disruptions
of sleep-wake cycles and circadian rhythms is the cap-
acity to integrate a number of new detailed objective
measures (Table 2). These complement extended self-
report measures of daily fluctuations in sleep, mood, en-
ergy or physical activity. They include extended periods
of actigraphy (for example, typically at least two weeks),
as well as 24- to 72-hour assays of body temperature
and 24-hour fluctuations in cortisol or melatonin (in-
cluding under controlled environmental parameters,
such as light exposure). Even though actigraphy mea-
sures are indirect and somewhat more variable (at least
in the short term) than other circadian markers, be-
cause of other behavioral and homeostatic influences,
they have consistently been found to correlate with
the circadian rhythm of endogenous melatonin and body
temperature [242-249]. Other new technologies, such as
smart phone applications, permit home monitoring of
extended periods of sleep-wake cycle behavior and
patterns of physical activity.
Within the research environment, the introduction of dir-
ect ecological monitoring systems [250,251] continues to
provide important new insights into the daily patterns of
physical activity, daytime resting, eating and other key so-
cial behaviors, alongside data related to subjective energy or
mood levels. These types of studies have the capacity toreveal important longitudinal associations between daytime
activity, sleep-wake cycle timing and mood and other psy-
chological and neuropsychological variables.
Markedly delayed sleep phase in young people with
depression
When the various sleep-wake technologies are applied in
younger subjects in the early phases of major mood dis-
orders, a quite different pattern of sleep and circadian
rhythms emerges in comparison to young persons with-
out mood disorders or middle-aged subjects with mood
disorders. Our own studies highlight two key aspects in
young persons with mood disorders, namely: (a) the pre-
dominance of delayed sleep phase (that is, not only go-
ing to bed later, but also rising later) [123] rather than
the more characteristic pattern of phase advance that
has traditionally been linked with more severe forms of
depression in mid and later-life; and, (b) a late dim light
melatonin onset (DLMO) compared to values classically
found in young healthy persons [42,212]. This delayed
pattern of the sleep-wake cycle and endogenous circa-
dian rhythms is most marked in those with bipolar than
unipolar phenotypes [123,212]. Importantly, longitudinal
prospective studies are needed to identify sleep-wake
or circadian predictors of mood disorders early in the
course of illness. Notably, promising findings in youth
have highlighted the predictive value of sleep problems
and specific polysomnographic (PSG) markers for the fu-
ture development of mood disorders [252-255] and the
transition from unipolar to bipolar depression [256].
Such technologies can also be applied in older subjects
with late-life depressive or early neurodegenerative dis-
orders. Here, our data shows that greater nocturnal
wakefulness as measured by actigraphic monitoring
Table 2 Currently available measurement systems for sleep and circadian rhythms
Measurement system Key features Proposed use
Self-report Prolonged reporting (for example, two weeks or more) of sleep timing, latency,
quality and duration, daily mood, daytime physical activity
- Identification of insomnia,
dysfunctional sleep and circadian-
rhythms.
Cross sectional questionnaires of sleep quality, excessive daytime sleepiness,
fatigue, presence of sleep disordered breathing and circadian rhythms;
- Characterization of the sleep-wake
cycle.
Smart phone technologies now allow daily recording of sleep schedules and
disturbances, as well as daytime physical activity patterns
- Assessment of treatment response.
Polysomnography Laboratory or ambulatory monitoring of nocturnal sleep - Differential diagnosis of various sleep
disorders.
- Characterization of sleep macro/
microarchitecture.
Actigraphy Indirect measure of the sleep-wake cycle especially convenient for multiday
ambulatory assessment
- Identification of insomnia,
dysfunctional sleep and circadian
rhythms.
At least one week of monitoring, (including weekdays and weekends) - Characterization of the sleep-wake
cycle.
Key differentiation of patterns of sleep onset, offset, daytime activity and napping - Assessment of treatment response.
Some monitors can simultaneously record patterns of light exposure and
estimate energy expenditure
Melatonin assays Dim light melatonin onset protocol in controlled laboratory settings or at home - Characterization of circadian rhythms
- Assessment of treatment response.
From saliva, urine or blood - Can support diagnosis of some
circadian rhythm sleep disorders
Core body temperature
monitoring
24-hour recording in controlled laboratory settings - Characterization of circadian rhythms
- Assessment of treatment response
From ingested wireless probe or rectal probe - Can support diagnosis of some
circadian rhythm sleep disorders
Cortisol assays 24-hour recording - Characterization of circadian rhythms
From saliva, urine or blood - Assessment of treatment response
Vigilance monitoring 24-hour recording in controlled laboratory settings - Characterization of circadian rhythms
- Psychomotor Vigilance Task (PVT) - Assessment of treatment response
- Wake EEG
- Multiple Sleep Latency test
The PVT or similar tasks are now available on smart phone applications
Cardiovascular
monitoring
Continuous or repeated measures of blood pressure and heart rate parameters
across 24 hours in controlled laboratory settings
- Characterization of circadian rhythms
- Assessment of treatment response
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pression [43], mild cognitive impairment [257], and
REM sleep behavior disorder in Parkinson’s disease
[258]. However, in these cohorts, even cross-sectional
self-report measures of sleep quality appear to be useful
correlates of phenotypic features, including depression
[259] and neuropsychological impairment [260].
Several PSG studies of persons with major depressive
disorders have been conducted. Yet, PSG is costly and
time consuming, often requires an adaptation night and
requires time intensive scoring by sleep technicians. By
contrast, self-report questionnaires, actigraphic record-
ings and sleep-wake cycle diaries are more accessible
screening and measurement tools (Table 2). However,there is a clear need to link this new emphasis on ex-
tended actigraphic measurements of both sleep-wake
cycle and circadian profiles with both PSG and more de-
tailed measures of the full range of other indicators of
circadian timing and synchrony (that is, body temperature,
cortisol, melatonin and immune measures).
Therapeutic approaches focused on correction of sleep-
wake and circadian disturbance in major depression
While there is a long tradition of studies examining the
effects of sleep-wake or circadian interventions in per-
sons with major mood disorders (see Table 3), they do
not figure prominently in major therapeutic guidelines
for these common conditions [261,262]. By comparison
Table 3 Therapeutic approaches for sleep and circadian disruptions in association with major depression
Therapeutic approach Target and rationale
Psychoeducation ● Understanding sleep-wake and circadian regulation mechanisms and the processes through which sleep and
circadian disturbances can be initiated and maintained
● Linking changes in sleep quality, quantity and 24-hour sleep-wake cycles to onset and relapse of mood
disorders
● Promoting awareness of how daytime and nighttime behaviors and environmental factors influence sleep-
wake and circadian rhythms (that is, sleep hygiene)
N.B. These interventions are not considered to be efficient when used by themselves, but can be helpful in
conjunction with other cognitive-behavioral interventions
Cognitive restructurig [286-288] ● Identifying and adjusting dysfunctional beliefs contributing to the maintenance of sleep difficulties
● Understanding the influence of perceptions on sleep quality and daytime functioning
● Establishing realistic expectations about sleep
● Learning techniques to prevent evening/nighttime ruminations
Structured behavioral changes
[143,266-272]
● Stimulus Control Therapy
Aiming to reestablish positive associations between the bedroom and sleeping by: a) keeping the bedroom
solely for sleep and sexual activities; and b) leaving the bedroom if awake for more than 15 minutes
● Bed Restriction Therapy
Using sleep pressure to enhance sleep consolidation by: a) limiting the sleep opportunity window to the
habitual time spent asleep; and, b) increasing this window progressively as sleep efficiency (that is, ‘total sleep
time’/‘time in bed’) improves
● Rescheduling
Progressive delay/advance of the sleep-wake and light–dark cycles
● Regularization of wake-up times (emphasizing the importance of keeping the same wake-up times on
weekends)
● These techniques provide patients with simple therapeutic tools that can subsequently be used
independently in case of relapse
Sleep deprivation [89,289-291] ● Can induce acute antidepressant effect
● Can be used prior to sleep-wake rescheduling to facilitate sleep-wake phase shifting
● May be useful to hasten and potentiate the response to phototherapy or cognitive-behavioral therapy
N.B. Caution is warranted as sleep loss can trigger mania/hypomania episodes in patients with unipolar or
bipolar depression
Intensive Sleep Retraining [292] ● While being monitored with polysomnography over a 25-hour protocol, patients are repeatedly given short
sleep opportunities, each time being awoken shortly after achieving sleep (the progressive increase of sleep
pressure is believed to facilitate multiple experiences of rapid sleep onset)
● This novel conditioning technique may be especially promising for patients with depression and sleep/
circadian disturbances because of the combined effects of acute partial sleep deprivation and subsequent
improvement of sleep onset and other sleep parameters
N.B. Caution is warranted as sleep loss can trigger mania or hypomania episodes
Social rhythms therapy for bipolar
disorder [265]
● Integrated behavioral, interpersonal and psychoeducational therapy focusing on:
- Regularizing daily activity rhythms (that is, eating, sleeping, leisure/work activities, social meetings)
- Managing biological or psychosocial factors susceptible of dysregulating biological rhythms
● Based on a model of bipolar disorder in which a genetic predisposition to circadian disturbances contributes
to bipolar symptoms
Relaxation training [293-296] ● Techniques commonly used for insomnia include: progressive muscle relaxation, diaphragmatic breathing,
autogenic training and imagery training
Phototherapy [271,273-278] ● Exposure to bright light (especially in the short blue to green wavelengths) has antidepressant and
chronobiotic effects
● To advances circadian rhythms:
Morning exposure to bright light and evening exposure to dim light
● To delay circadian rhythms:
Evening exposure to bright light and morning exposure to dim light
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Table 3 Therapeutic approaches for sleep and circadian disruptions in association with major depression (Continued)
● Extended exposure to darkness can reduce manic symptoms in bipolar disorders
● Actimeters with light sensors can be used to monitor adherence
Hypnotics/Sedatives ● In those with delayed circadian rhythms, can be used in the short-term to help realign the sleep phase to a
regular schedule
Stimulant-wakefulness agents ● In those with daytime fatigue, low energy, reduced locomotor activity and daytime sleeping can been used
to increase the wake period




● Often result in longer-term correction of sleep-wake cycle and circadian phase after recovery from depression
– assumed via monoamine related mechanisms
● Traditionally result in REM-sleep suppression and in the short-term may disturb sleep architecture
● Those with more obvious noradrenergic properties have been used (with daytime or morning
administration) to also promote daytime activity and arousal and help reduce subjective fatigue
● Those with classical serotoninergic properties, when given at night, may increase arousal and wakefulness.
While serotoninergic inputs to the SCN are expected to increase wakefulness, selective serotonin reuptake
inhibitors (SSRIs) have not proved to be very useful in the management of more prolonged fatigue states
compared with either nighttime sleep-promoting agents or daytime stimulants
Lithium [299-302] ● Inhibits GSK-3β, a kinase involved in the circadian regulation of the SCN
● Modulates circadian rhythms (possibly by lengthening the circadian period or delaying endogenous rhythms)
● Can enhance the therapeutic effects of combined sleep deprivation and phase advance in people with
bipolar disorders
● Known to decrease retinal sensitivity to light and could possibly influence melatonin’s sensitivity to light
Melatonin [303-305] ● Can advance sleep onset in those with delayed sleep phase syndrome
● Could possibly improve the sleep-wake rhythm and prolong sleep in elderly people with advanced sleep
phase syndrome (insufficient empirical data)
● Reduce sleep onset latency and improve sleep efficiency (most consistent effects in elderly insomniac)
N.B. Not recommended for children and adolescents under 18 years of age because of insufficient safety data
(MIMS online)
Melatonin analogues [306-314] ● Direct effects on sleep onset with potential additional effects via other monoamine related mechanisms
● Can reduce sleep onset latency and increase sleep duration in patients with insomnia
● Could possibly be used to phase shift endogenous melatonin rhythms
● Could possibly improve subjective sleep and increase sleep consolidation and SWS in patients with major
depression
● Can advance endogenous rhythms in older adults
N.B. Not recommended for children and adolescents under 18 years of age because of insufficient safety data
(MIMS online)
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modification of monoamine systems, and similarly psy-
chological therapy trials focusing on cognitive, interper-
sonal and related behavioral factors, the evidence-base
for sleep-wake and circadian interventions is only mod-
est. Consequently, in major depression guidelines sleep
and circadian-relevant interventions are referred to only
as a general management strategy (for example, enhan-
cing ‘sleep hygiene’ or promoting physical activity) or
sleep and circadian related phenomena are viewed as
possible presentations of alternative primary medical
diagnosis (for example, sleep apnea).
As most treatment guidelines (based on DSM-IV or
International Classification of Diseases (ICD)-10) utilizea simple severity model (that is, mild/moderate/severe),
for the clinical management of major depression it is not
surprising that an approach focusing on a putative sleep-
wake cycle or circadian pathophysiology is not central to
treatment selection for people with major depressive dis-
orders. Another difficulty is that relevant information is
distributed across a broader literature notably in relation
to bipolar disorder, primary insomnia, other primary sleep
disorders, chronic fatigue, geriatric medicine and other
areas of general medicine. One of the more attractive
features of the various sleep and circadian-based anti-
depressant approaches (behavioral or pharmacological)
available appears to be the relatively rapid onset of action.
Given the much slower onset of action of conventional
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surprising that this relative benefit is underemphasized in
clinical practice [263,264].
Available circadian-based interventions
Despite these conceptual and organizational biases, it is
possible to construct an extensive list of potentially
therapeutic sleep-wake cycle and circadian interventions
available for use in persons with major mood disorders
(Table 3). Rather than providing separate information
about nighttime/sleep vs. daytime/wake activity, this ap-
proach focuses on collating these perspectives within
one framework focused on optimizing the 24-hour sleep-
wake cycle. Additionally, it provides a more in-depth ex-
planation of key aspects of circadian biology (for example,
the importance of rising time and exposure to morning
sunlight to suppress melatonin - see Figures 1 and 4). The
tying of these factors with broader notions of social
rhythms is also encouraged [265]. For those requiring
more specific modifications of sleep-related phenom-
ena, a range of key behavioral strategies is relevant
[143,266-272]. Within this context, the use of specific
forms of light therapy or daytime light exposure has
received considerable attention [271,273-278].
Pharmacological approaches to sleep-wake and circadian
systems
A wide range of pharmacotherapies has been utilized to
manage sleep disturbance and related mood and cogni-
tive phenomena [for a review, see [279]. Until recently,
these have relied heavily on non-specific sedative strat-
egies at night or stimulant-based approaches during day-
light hours. These approaches, particularly when they
are combined with appropriate other behavioral inter-
ventions, are likely to produce some short-term benefits.
The place of traditional monoamine-based antidepres-
sant strategies in the management of sleep and circadian
related disorders remains controversial. While serotonin-
ergic inputs to the SCN are consistent with the concept
that these agents have the capacity to affect circadian
patterns directly, the effects of these therapies on circa-
dian parameters have not been studied extensively.
More often, the effects of monoamine-based therapies
on key sleep parameters (sleep latency, REM latency,
sleep architecture and suppression of REM sleep) have
received attention [280-282]. The older tricyclic agents
(TCAs) are still widely prescribed for their sedative
properties and the extent to which more recent SSRI
and selective norepinephrine reuptake inhibitor (SNRI)
agents disturb sleep during the early phases of therapy
(resulting in co-prescribing of hypnosedatives, TCAs or
low dose antipsychotics) has been widely reported. Given
the essentially activating inputs of serotonin to the SCN
(see Figure 1), this effect is not surprising. It certainly raisesquestions about the optimal timing of administration of
these compounds, which for convenience (or to minimize
other side-effects) are often taken at night. The new ques-
tion is whether any of the more recent melatonin-based
products (particularly when taken at night) offer any spe-
cific benefits, from a sleep architecture, sleep-wake
cycle, circadian or mood disorders perspective, com-
pared with the conventional non-specific approaches.
Melatonin-based therapies
While melatonin has not traditionally been considered
to be a viable antidepressant alone [283-285], the regis-
tration of agomelatine in the European Union and inter-
nationally (but not in the USA) as a treatment for major
depression has again raised questions as to whether
melatonin itself has significant antidepressant properties.
What is more likely is that there are specific subgroups
of those with major depressive disorders (and most obvi-
ously those with depression with chronic insomnia, cir-
cadian dysfunction, seasonal features or bipolar
depression) who are likely to derive antidepressant bene-
fits from melatonin, agomelatine or other melatonin-
based analogues. Although agomelatine has been evalu-
ated for short and longer-term efficacy by the European
Medicines Agency, it has not been presented to the FDA
for registration in the USA. Further, there has been con-
siderable academic debate as to the relative efficacy of
agomelatine compared with placebo or other available
antidepressant agents [315-317]. Importantly, the differ-
ential effects of agomelatine as compared with SSRIs on
sleep architecture has only recently been subject to in-
vestigation, with an initial study favoring the short-term
benefits of agomelatine on key sleep parameters [318].
There is an ongoing need for further comparative stud-
ies. A very recent report suggests that another melatonin
analogue, ramelteon, when taken adjunctively with other
therapies may have benefits in preventing relapse into
depression in patients with bipolar disorder [239].
Phase advance as a therapeutic strategy
What is most apparent is that therapies that result in
phase advance in circadian rhythms are largely antidepres-
sant in effect. The best studied examples are morning
bright light therapies, partial sleep deprivation and
enforced early morning rising [319-322]. Information
from relevant pharmaceutical studies indicate that SSRI
drugs induce a phase advance in the firing of SCN neu-
rons in culture and that agomelatine induces a phase ad-
vance in endogenous circadian rhythms [322,323]. These
phase-advancing effects of monoamine and melatonin-
acting agents are contrasted with those of lithium, which
can induce a phase delay [290,324-326]. However, in clin-
ical studies lithium has its principal effect on mania (and
prevention of manic relapse) rather than acute depressive
Managing your sleep-wake cycle
Depression usually leads to:
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Worksheet for activity planning and sleep-wake cycle management
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Figure 4 Psychoeducation and monitoring worksheet for patients with mood disorders and sleep-wake and circadian disturbance.
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Table 4 Planning an individualized sleep and circadian intervention
A. Initial clinical assessment and enrollment to two weeks of systematic assessment
1. Clinical assessment of depression Assessment for key features indicative of circadian-dependent mood disorders including:
● Positive family history of mania or circadian rhythm sleep disorders
● Diurnal or seasonal sensitivity
● Easy destabilization by changes in time-zones or changes in regular sleep pattern
● Non-restorative sleep
● Daytime fatigue
● Difficulty falling asleep
● Late morning rising or waking up early in the morning
● Oversleeping
● Overeating or weight gain
● Screen for other sleep disorders, such as restless legs syndrome or sleep apnea
2. Evaluation of key sleep and
circadian phenotypes
Self-report/self-monitoring over two-weeks (see Figure 4) using smart phone or paper-pencil, particularly
focusing on:
● Chronotypes on morningness-eveningness scales
● Time of sleep onset /offset and differences between work/schooldays and weekend schedules
● Duration of sleep
● Waking from sleep
● Pre-sleep hyperarousal symptoms
● Night sweats – raised temperature during sleep
● Timing and level of daytime physical activity
● Atypical circadian mood variations
Objective measures including:
● Two-weeks of continuous actigraphy/sleep diaries
● Dim light melatonin onset assays
B) Information and treatment planning sessions
1. Psychoeducation with regards to
the human sleep and circadian
systems
Key elements include:
● Explanation of the biology of the human clock
● Illustration of the normal 24-hour cycle in sleep and activity and synchronization with hormonal, immune,
body temperature and other key physiological elements
● Emphasis on setting the clock through morning rising, appropriately timed light exposure, regularity of
activity cycles, daytime physical activity, bedtime schedules and nighttime practices
● Linking to eating behavior and risks to obesity and metabolic function
2. Set specific behavioral elements Key decisions include:
● Set sleep offset time (or schedule for gradual phase advance/delay relative to current waking time) with
special care to avoid sleep loss induced mania/hypomania episode in people at risk for bipolar disorder
● Set daily activity schedules
● Emphasize morning light exposure (natural or through specific devices with special care to avoid bright
light induced mania/hypomania in people at risk for bipolar disorder)
● Discuss regular sleep onset time expectations
● Set sleeping conditions relative to light exposure and temperature
3. Introduce self-report or objective
measurement techniques for this
period
Key elements include (see Figure 4):
● Daily monitoring of actual sleep onset /offset, sleep duration and sleep quality
● Continuous recording of actual daytime physical activity
● Daily mood and fatigue monitoring
● Monitoring of substance use and eating behavior
● Monitoring of other behaviors that could adversely affect sleep including excessive or poorly timed napping
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Table 4 Planning an individualized sleep and circadian intervention (Continued)
C) Review progress at two weeks
Key elements are:
● Adherence to sleep offset time, light exposure and degree of actual physical activity
● Evaluate changes in daily mood, fatigue, sleep quality
D) If inadequate clinical progress:
Consider:
● Adherence and planning issues
● Adjunctive strategies to be considered:
- Earlier/later or augmented light exposure
- Melatonin supplementation with careful planning of ingestion time
E) Review progress at four weeks
If inadequate clinical progress: Consider:
● Adherence and planning issues
● Adjunctive strategies to be considered:
- Melatonin-based antidepressant strategies
- Other conventional antidepressant strategies
- Alternative daytime stimulant or nighttime sedation strategies
F) Review progress at six- to eight-weeks
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vestigation for their capacity to induce a phase advance or
restore normal circadian patterns (acting via effects on
other regulatory proteins, such as CK1-delta). However, it
is not yet known whether such agents have antidepressant
or other mood stabilizing properties (See [58]).
The development of novel therapeutic strategies for
circadian-based mood disorders (and other closely-related
neuropsychiatric syndromes) is now likely to focus on be-
havioral or pharmacological strategies that: (i) phase ad-
vance circadian timing, as this is the strongest correlate of
an antidepressant response. This may be achieved by fo-
cusing on SCN molecular targets to alter period length or
by making greater use of behavioral or pharmacological
approaches that entrain or enhance melatonin secretion;
(ii) entrain rhythms more robustly in those clinical situa-
tions in which there is strong evidence of only weak link-
age to the day-night cycle or evidence of chaotic or
frequently-changing patterns. In clinical psychiatry, the
depressive and mixed mood phases of bipolar disorder are
likely to be the main targets. These may include strategies
akin to lithium and may be associated with phase delay or
phase advance in timing. Current melatonin-based strat-
egies may also be central to this approach; and (iii) restore
normal internal synchrony of key behavioral, neurohor-
monal, metabolic, autonomic and immunological systems.
This may be achieved by a variety of existing mechanisms
(for example, behavioral and pharmacological approaches
to enhance melatonin release) or novel mechanisms that
target the molecular mechanisms of the SCN, melatoninrelease by the pineal gland or factors that modulate other
key hypocretin/orexin or leptin-associated mechanisms.
Planning a mood disorder intervention based on sleep
and circadian therapies
In those subjects with mood disorders who have been
identified as presenting key features consistent with
underlying perturbations of sleep-wake cycle or circadian
systems, it is possible to set out a therapeutic program
over a six- to eight-week period (Table 4). The key fea-
tures are strong reliance on self-monitoring, highly struc-
tured planning of waking, activity, sunlight (or adjunctive
light) exposure and sleep schedules. Strong educational el-
ements about the underlying neurobiology and frequent
reviews of difficulties encountered, as well as careful mon-
itoring of the mood disorder and associated risks are es-
sential (see Figure 4). In this process, decisions about
adjunctive specific pharmacotherapy for either the circa-
dian or depression elements are delayed until at least four
weeks, although the use of melatonin may be considered
after two weeks.
A key consideration in such programs is the age of the
patients and the direction and degree of phase shift. In
younger subjects, there is a normal developmental change
in sleep and circadian rhythms with a shift towards phase
delay throughout the late adolescent period. Hence, phase
advancing strategies in this group need to be cognizant
of a return to normal developmental patterns. For older
subjects, the converse may be in operation with a marked
shift towards earlier sleep onset and sleep offset times. In
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to focus on the degree and timing of daytime activity
and other related behaviors (for example, controlling
excessive daytime napping) as it is to focus on night-
time behavior.
Limitations of circadian-based assessments and
therapeutics
At this time, the style of prolonged actigraphy-based
sleep-wake cycle measurements - that are essential for
personalizing treatment regimens - are not in common
clinical use. Hence, there is a need to introduce them
more widely and for their use to be augmented by ap-
propriate prolonged reports of mood, behavior and sleep
quality (that is, ‘mood, sleep and behavior diaries’ – see
Figure 4). Importantly, such measures are only indirect
indicators of underlying circadian biology. That is, they
cannot be used to confirm the presence of internal
desynchrony, as this requires simultaneous monitoring
over at least a 24-hour period of various endogenous
measures, such as melatonin, cortisol or core body
temperature. However, as body temperature record-
ings and other physiological measures become more
widely available, these may also become more consist-
ently used, especially if empirical studies continue to re-
fine our understanding of the evolution of these markers
across the various stages of affective illnesses.
From a therapeutic perspective, the direct or indirect
effects of many available psychotropic compounds on
circadian biology have not yet been clarified. Although
the availability of melatonin and melatonin-based ago-
nists has already had an impact in the insomnia field,
its direct relevance to those with primary mood (in-
cluding both unipolar and bipolar) disorders is still
unclear. With the emergence of hypocretin/orexin an-
tagonists, it is likely that further complexities will be-
come apparent.
The imposition of rigid behavioral or timing schedules
on different groups of patients is clinically challenging.
In general terms, this is particularly so for younger sub-
jects who experience a normal adolescent period of
phase delay (and may also need to fit with school or
other educational schedules) and older subjects who
may be experiencing significant phase advance. Add-
itionally, those with different underlying chronotypes
(‘morningness’ vs. ‘eveningness’) will vary in their cap-
acity to incorporate major changes in daytime schedul-
ing into their lifestyle.
Summary
There is an urgent need in clinical psychiatry to advance
more personalized approaches to syndrome description
and treatment selection. In our view, this goal is now
within reach, at least for that subpopulation of peoplewith mood disorders who have clear evidence of dis-
turbed circadian physiology. Current estimates among
adult populations (based on the bipolar spectrum con-
cept) indicate that this may be in the order of 40% of
middle-aged patients [327]. This departure from trad-
itional antidepressant strategies has been possible due to
four factors: (i) major advances in the basic neurosci-
ences of sleep and the related circadian systems, with
great detailing of the molecular machinery of the circa-
dian clock and the processes by which it both re-
sponds to external cues and regulates internal physiology;
(ii) developmental studies of sleep-wake cycle and circa-
dian parameters of people (teenagers, young adults and
older persons) close to the onset of their major depression;
(iii) use of more objective and specific measurement as-
says and longer-term monitoring systems for circadian
dysfunction in humans; and, (iv) development of new and
more specific behavioral (incorporating education, sleep
rescheduling, light exposure and daytime physical activity)
and pharmacological (largely melatonin-based) therapies
for treatment of mood disorders. A much greater focus on
circadian-based major depressive disorders has the poten-
tial to deliver clinical psychiatry what it has always
desired – a diagnostic grouping linked with strong object-
ive measures of illness state and a basis for more rational
treatment selection and monitoring of response to
targeted behavioral or pharmacological interventions.
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